Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week

BACKGROUND: MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support once-weekly dosing. SETTING: A phase 1, open-label, proof-of-concept stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Schürmann, Dirk, Jackson Rudd, Deanne, Schaeffer, Andrea, De Lepeleire, Inge, Friedman, Evan J., Robberechts, Martine, Zhang, Saijuan, Liu, Yang, Kandala, Bhargava, Keicher, Christian, Däumer, Martin, Hofmann, Jörg, Grobler, Jay A., Stoch, S. Aubrey, Iwamoto, Marian, Ankrom, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740605/
https://www.ncbi.nlm.nih.gov/pubmed/34654041
http://dx.doi.org/10.1097/QAI.0000000000002834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740605/
https://www.ncbi.nlm.nih.gov/pubmed/34654041
http://dx.doi.org/10.1097/QAI.0000000000002834

Ejemplares similares